Zacks Investment Research upgraded shares of Zealand Pharma A/S (NASDAQ:ZLDPF) from a sell rating to a hold rating in a research report released on Tuesday.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company’s pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark. “

Zealand Pharma A/S (ZLDPF) remained flat at $17.75 during midday trading on Tuesday. The stock has a 50 day moving average of $17.74 and a 200-day moving average of $17.03. Zealand Pharma A/S has a one year low of $14.95 and a one year high of $18.61. The stock’s market capitalization is $454.03 million.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZLDPF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.